Introduction
Amiodarone, a benzofuran derivative, was introduced originally in 1967 as an anti-anginal agent and was later found to have antiarrhythmic properties. It is a Class III antiarrhythmic (Vaughan Williams 1970 , Lancet 1979 and has been shown to be effective in both atrial and ventricular arrhythmias, and especially in the Wolff Parkinson White syndrome (Lancet 1979, Rosenbaum et al. 1976) . It has no product licence in the United Kingdom and is available only for nominated patients. Crystals of the drug are invariably deposited in the cornea.
We report our experience with amiodarone in treating 8 patients, 3 of whom developed tolerance.
Results
Eight patients are described, 6 males and 2 females. Clinical details and results are summarized below.
Case 1: Miss M L, aged 62, had systemic lupus erythematosus diagnosed in 1969 and has required long-term treatment with prednisone. Two years ago she developed paroxysmal atrial fibrillation plus ventricular ectopics, resistant to digoxin. Following the introduction of amiodarone 200 mg daily, no further arrhythmias have occurred. Case 3: Mr J C, aged 36, developed a calcified ventricular aneurysm following myocardial infarction at the age of 29, and for 20 months experienced paroxysmal ventricular tachycardia which was resistant to mexiletine and Kinidin Durules. Since starting treatment 19 months ago with amiodarone 200 mg daily he has had no further attacks.
Case 4: Mr I J, aged 63, had very disabling paroxysms of atrial flutter for 10 years, occurring 5 days a week. Digoxin, quinidine, disopyramide and propranolol all failed to help. Amiodarone was started 26 months ago at a dosage of200 mg daily. The attacks decreased to one every 8-10 days for a year. Paroxysms then became more frequent. Amiodarone was increased to 200 mg twice daily. At 22 months the attacks increased to one every 2 days; on increasing the dosage to 200 mg three times daily he became asymptomatic. Three months ago his symptoms again recurred and amiodarone was increased to 200 mg four times daily.
Case 5: Mr P M, aged 55, had paroxysmal atrial flutter for 20 years, gradually worsening. He had daily attacks, lasting up to 18 hours, which were unpleasant and resistant to digoxin, propranolol, disopyramide and phenytoin, singly or in combination. Amiodarone 200 mg daily reduced the attacks to a few hours every 4 days for the first 4 months. Attacks then occurred daily. At 7 months the dose was increased to 200 mg twice daily, and once again the attacks reduced to one every 4 days. Due to gastrointenstinal side effects the dose was reduced to 300 mg daily. At 27 months he rarely has a paroxysm.
Case 6: Mr P A, aged 66, had paroxysmal atrial flutter for 6 years which failed to respond to digoxin and propranolol. Amiodarone 200 mg daily produced slight improvement but was discontinued after one month because he developed left bundle branch block.
Case 7: Mrs E R, aged 64, had a diagnostic laparotomy in May 1978, after which she developed supraventricular tachycardia and was found to have Wolff Parkinson White syndrome. The attacks were resistant to intravenous practolol, disopyramide and verapamil. Amiodarone was started 15 days postoperatively. From several attacks a week, the incidence declined to 2 in the month between commencing amiodarone and her death from a myeloproliferative disorder.
Case 8: Mr L W, aged 42, was diagnosed as having ischaemic heart disease and mitral valve prolapse, and underwent triple coronary artery bypass graft, left ventricular aneurysmectomy and mitral valve repair in July 1979. One month later he developed episodes of palpitation daily, especially on effort, and was found to have atrial flutter with 2:1 block. The block changed to 1: 1 on effort. Digoxin and propranolol over 3 weeks were ineffective, but soon after starting amiodarone 200 mg three times daily periods of sinus rhythm began to occur; they became progressively longer and 20 days later the arrhythmia was abolished. Now he occasionally complains of palpitation. He also notices lines across his vision but has only minor corneal microdeposits.
.
Discussion
All 8 patients received considerable benefit from amiodarone, and thus our experience is similar to that of previous workers (Rosenbaum et al. 1976 , Chamberlain & Clark 1977 , Leak & Edjdt 1979 . Death from another cause in one patient, and the development of left bundle branch block (with withdrawal of the drug at one month) in another patient, prevented longterm evaluation. The other 6 patients have been treated for 10-28 months. Three patients (all with paroxysmal atrial flutter) exhibited tolerance to amiodarone requiring increased dosage at 4-14 months after the introduction of amiodarone therapy.
Side effects of amiodarone were not troublesome. All patients were seen at six-monthly intervals by an ophthalmic surgeon. Slit-lamp examination revealed corneal microdeposits in all patients. Only one patient had ocular symptoms. One patient developed bundle branch block which is stated to be a direct effect on a previously damaged fascicle.
Thus we have found amiodarone to be a very useful drug in resistant arrhythmias, although it is important to watch for the development of tolerance.
